The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital.
Maria-Magdalena ConstantinStefana BucurCostina-Cristiana MutuElena PoenaruRodica OlteanuRazvan Adrian IonescuAlin Codrut NicolescuFlorentina FurtunescuTraian ConstantinPublished in: Journal of personalized medicine (2021)
Psoriasis is an immune-mediated chronic inflammatory skin disease with extracutaneous manifestations, that affects about 1-3% of the world's population. The disease is not life-threatening, but the disability which comes with it is comparable to the disability caused by other serious chronic diseases, such as oncologic or cardiovascular disease. Several risk factors, such as infections, stress, smoking, excessive alcohol consumption and genetic predisposition have been involved in inducing psoriasis. Smoking status is a risk factor for many chronic diseases, including psoriasis. Moreover, recent studies have tried to answer the question of whether smoking also influences the response to biologic therapy in patients with psoriasis. Through the current study, our intention is to find out how smoking affects the response to biologic treatment. A hospital-based cross-sectional, observational, non-interventional, retrospective study of moderate and severe psoriasis patients receiving biologic treatment was developed. Two groups were defined based on smoking status: group 1 included smokers (more than 10 cigarettes/day) and former smokers, and group 2 included non-smokers. The data that resulted from the analysis of the cohort of patients demonstrate that smoking status does not affect the response of biologic therapy in patients with moderate and severe psoriasis.
Keyphrases
- smoking cessation
- replacement therapy
- rheumatoid arthritis
- cardiovascular disease
- cross sectional
- risk factors
- atopic dermatitis
- alcohol consumption
- end stage renal disease
- healthcare
- multiple sclerosis
- ejection fraction
- type diabetes
- emergency department
- chronic kidney disease
- machine learning
- metabolic syndrome
- prostate cancer
- early onset
- oxidative stress
- dna methylation
- mesenchymal stem cells
- genome wide
- gene expression
- peritoneal dialysis
- combination therapy
- rectal cancer
- big data
- radical prostatectomy
- artificial intelligence